{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:02:31Z","timestamp":1791838951249,"version":"4.3.4"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Diabetes mellitus and cancer are two expanding global health burdens that share upstream determinants, yet diabetes may also contribute to malignancy risk through hyperglycaemia\/AGE-related stress, insulin resistance with compensatory hyperinsulinaemia, obesity-related inflammation, and tumour microenvironment modulation. This narrative review synthesizes mechanistic plausibility and critically appraises the highest-level clinical evidence on the oncologic safety signals of glucose-lowering therapies, with a focus on cancer incidence captured within randomized diabetes trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>argeted searches of PubMed\/MEDLINE and Embase were complemented by manual reference screening. Mechanistic and translational data were summarized separately from clinical evidence. For each drug class, we prioritized pivotal randomized controlled trials and cardiovascular outcome trials (phase 3\u20134, large, practice-defining), extracting malignancy reporting collected as adverse events\/serious adverse events or events of special interest. When randomized evidence was limited, high-quality meta-analyses and selected real-world studies were used for context, clearly distinguished from prespecified randomized evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Metformin shows a predominantly neutral effect on cancer incidence, with possible indirect protective signals but no trials specifically designed to assess chemoprevention. Thiazolidinediones demonstrate an overall neutral malignancy profile, with early concerns regarding bladder cancer not confirmed in adjudicated analyses. GLP-1 receptor agonists and dual GLP-1\/GIP agonists consistently show no increase in overall or site-specific cancer risk, with emerging signals of reduced obesity-related malignancies. SGLT2 inhibitors display class-wide oncologic neutrality, with heterogeneous and inconclusive drug-specific patterns in meta-analyses. Randomized evidence confirms that insulin, including long-acting analogues, does not increase cancer risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current randomized evidence supports a predominantly neutral effect of antidiabetic therapies on cancer incidence, with some agents showing promising signals of protection. This interpretation is constrained by non-prespecified endpoints, limited oncologic adjudication, short follow-up relative to tumour latency, low site-specific event counts, and potential competing-risk effects. Dedicated long-term trials and registry-linkage strategies with cancer-focused endpoints are needed to clarify whether any therapies confer true protection or warrant targeted monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-026-04644-1","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:40:59Z","timestamp":1777876859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies"],"prefix":"10.1007","volume":"91","author":[{"given":"R.","family":"Modica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Liccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Zamponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nistor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Veroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"4644_CR1","doi-asserted-by":"publisher","unstructured":"S. Mendis, S. Davis, B. Norrving, Organizational update: the world health organization global status report on noncommunicable diseases 2014; one more landmark step in the combat against stroke and vascular disease. Stroke. 46(5), e121\u2013e122 (May 2015). https:\/\/doi.org\/10.1161\/STROKEAHA.115.008097","DOI":"10.1161\/STROKEAHA.115.008097"},{"key":"4644_CR2","doi-asserted-by":"publisher","unstructured":"H. Sun et al., IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (Jan. 2022). https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"4644_CR3","doi-asserted-by":"publisher","unstructured":"K.L. Ong et al., Jul., Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021, The Lancet, vol. 402, no. 10397, pp. 203\u2013234, 2023, https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6","DOI":"10.1016\/S0140-6736(23)01301-6"},{"issue":"3","key":"4644_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"F. Bray et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74(3), 229\u2013263 (2024). https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J. Clin."},{"key":"4644_CR5","doi-asserted-by":"publisher","unstructured":"B. Zhou et al., Nov., Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants, The Lancet, vol. 404, no. 10467, pp. 2077\u20132093, 2024, https:\/\/doi.org\/10.1016\/S0140-6736(24)02317-1","DOI":"10.1016\/S0140-6736(24)02317-1"},{"key":"4644_CR6","doi-asserted-by":"publisher","unstructured":"B.B. Duncan, D.J. Magliano, E.J. Boyko, IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050, Nephrology Dialysis Transplantation, Aug. 2025, https:\/\/doi.org\/10.1093\/ndt\/gfaf177","DOI":"10.1093\/ndt\/gfaf177"},{"key":"4644_CR7","unstructured":"www.who.int\/health-topics\/cancer#tab=tab_1."},{"key":"4644_CR8","unstructured":"www.who.int\/health-topics\/cancer#tab=tab_1, www.airc.it\/cancro\/informazioni-tumori\/cose-il-cancro\/numeri-del-cancro."},{"key":"4644_CR9","doi-asserted-by":"publisher","unstructured":"K.K. Tsilidis, J.C. Kasimis, D.S. Lopez, E.E. Ntzani, J.P.A. Ioannidis, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 350, g7607\u2013g7607 (Jan. 2015). https:\/\/doi.org\/10.1136\/bmj.g7607. no. jan02 1","DOI":"10.1136\/bmj.g7607"},{"key":"4644_CR10","doi-asserted-by":"publisher","unstructured":"M. Wang, Y. Yang, Z. Liao, Diabetes and cancer: Epidemiological and biological links. World J. Diabetes. 11(6), 227\u2013238 (Jun. 2020). https:\/\/doi.org\/10.4239\/wjd.v11.i6.227","DOI":"10.4239\/wjd.v11.i6.227"},{"key":"4644_CR11","doi-asserted-by":"publisher","unstructured":"V. Papa, A. Belfiore, Insulin receptors in breast cancer: Biological and clinical role. J. Endocrinol. Invest. 19(5), 324\u2013333 (May 1996). https:\/\/doi.org\/10.1007\/BF03347871","DOI":"10.1007\/BF03347871"},{"key":"4644_CR12","doi-asserted-by":"publisher","unstructured":"S.K. Garg, H. Maurer, K. Reed, R. Selagamsetty, Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes. Metab. 16(2), 97\u2013110 (Feb. 2014). https:\/\/doi.org\/10.1111\/dom.12124","DOI":"10.1111\/dom.12124"},{"key":"4644_CR13","doi-asserted-by":"publisher","unstructured":"American Diabetes Association, 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2019. Diabetes Care. 42(1), S34\u2013S45 (Jan. 2019). https:\/\/doi.org\/10.2337\/dc19-S004","DOI":"10.2337\/dc19-S004"},{"key":"4644_CR14","doi-asserted-by":"publisher","unstructured":"C. Elena et al., Feb., Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations, Curr. Pharm. Biotechnol., vol. 19, no. 15, pp. 1210\u20131220, 2019, https:\/\/doi.org\/10.2174\/1389201020666190102145305","DOI":"10.2174\/1389201020666190102145305"},{"key":"4644_CR15","doi-asserted-by":"publisher","unstructured":"K.K. Patel, K. Kashfi, Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs. Biochem. Pharmacol. 196, 114654 (Feb. 2022). https:\/\/doi.org\/10.1016\/j.bcp.2021.114654","DOI":"10.1016\/j.bcp.2021.114654"},{"key":"4644_CR16","doi-asserted-by":"publisher","unstructured":"M.S. Popoviciu et al., Aug., Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities., Int. J. Mol. Sci., vol. 24, no. 16, 2023, https:\/\/doi.org\/10.3390\/ijms241612676","DOI":"10.3390\/ijms241612676"},{"key":"4644_CR17","doi-asserted-by":"publisher","unstructured":"N.A. ElSayed et al., Jan., 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142025, Diabetes Care, vol. 48, no. Supplement_1, pp. S27\u2013S49, 2025, https:\/\/doi.org\/10.2337\/dc25-S002","DOI":"10.2337\/dc25-S002"},{"key":"4644_CR18","doi-asserted-by":"publisher","unstructured":"M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation, Science (1979)., vol. 324, no. 5930, pp. 1029\u20131033, May 2009. https:\/\/doi.org\/10.1126\/science.1160809","DOI":"10.1126\/science.1160809"},{"key":"4644_CR19","doi-asserted-by":"publisher","unstructured":"S. Yang et al., Activated IGF-1R inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination. Am. J. Physiology-Renal Physiol. 289(5), F1144\u2013F1152 (Nov. 2005). https:\/\/doi.org\/10.1152\/ajprenal.00094.2005","DOI":"10.1152\/ajprenal.00094.2005"},{"key":"4644_CR20","doi-asserted-by":"publisher","unstructured":"S.C. Lee, J.C. Chan, Evidence for DNA Damage as a Biological Link Between Diabetes and Cancer, Chin. Med. J. (Engl)., vol. 128, no. 11, pp. 1543\u20131548, Jun. 2015, https:\/\/doi.org\/10.4103\/0366-6999.157693","DOI":"10.4103\/0366-6999.157693"},{"key":"4644_CR21","doi-asserted-by":"publisher","unstructured":"C. Lee et al., Epigenetic regulation of Neuregulin 1 promotes breast cancer progression associated to hyperglycemia. Nat. Commun. 14(1), 439 (Jan. 2023). https:\/\/doi.org\/10.1038\/s41467-023-36179-8","DOI":"10.1038\/s41467-023-36179-8"},{"key":"4644_CR22","doi-asserted-by":"publisher","unstructured":"H. Xing, V. Yaylayan, Mechanochemically Induced Controlled Glycation of Lysozyme and Its Effect on Enzymatic Activity and Conformational Changes, J. Agric. Food Chem., vol. 67, no. 11, pp. 3249\u20133255, Mar. 2019, https:\/\/doi.org\/10.1021\/acs.jafc.9b00070","DOI":"10.1021\/acs.jafc.9b00070"},{"key":"4644_CR23","doi-asserted-by":"publisher","unstructured":"A. Berbudi, N. Rahmadika, A.I. Tjahjadi, R. Ruslami, Type 2 Diabetes and its Impact on the Immune System. Curr. Diabetes Rev. 16(5), 442\u2013449 (May 2020). https:\/\/doi.org\/10.2174\/1573399815666191024085838","DOI":"10.2174\/1573399815666191024085838"},{"key":"4644_CR24","doi-asserted-by":"publisher","unstructured":"X. Shi et al., Role of body mass index and weight change in the risk of cancer: A systematic review and meta-analysis of 66 cohort studies. J. Glob Health. 14, 04067 (Mar. 2024). https:\/\/doi.org\/10.7189\/jogh.14.04067","DOI":"10.7189\/jogh.14.04067"},{"key":"4644_CR25","doi-asserted-by":"publisher","unstructured":"N. Gray, G. Picone, F. Sloan, A. Yashkin, Relation between BMI and Diabetes Mellitus and Its Complications among US Older Adults. South. Med. J. 108(1), 29\u201336 (Jan. 2015). https:\/\/doi.org\/10.14423\/SMJ.0000000000000214","DOI":"10.14423\/SMJ.0000000000000214"},{"key":"4644_CR26","doi-asserted-by":"publisher","unstructured":"R.B. Goldberg, Cytokine and Cytokine-Like Inflammation Markers, Endothelial Dysfunction, and Imbalanced Coagulation in Development of Diabetes and Its Complications, J. Clin. Endocrinol. Metab., vol. 94, no. 9, pp. 3171\u20133182, Sep. 2009, https:\/\/doi.org\/10.1210\/jc.2008-2534","DOI":"10.1210\/jc.2008-2534"},{"key":"4644_CR27","doi-asserted-by":"publisher","unstructured":"Z. Zelenko, E.J. Gallagher, Diabetes and Cancer. Endocrinol. Metab. Clin. North. Am. 43(1), 167\u2013185 (Mar. 2014). https:\/\/doi.org\/10.1016\/j.ecl.2013.09.008","DOI":"10.1016\/j.ecl.2013.09.008"},{"key":"4644_CR28","doi-asserted-by":"publisher","unstructured":"P. Berraondo et al., Cytokines in clinical cancer immunotherapy. Br. J. Cancer. 120(1), 6\u201315 (Jan. 2019). https:\/\/doi.org\/10.1038\/s41416-018-0328-y","DOI":"10.1038\/s41416-018-0328-y"},{"key":"4644_CR29","doi-asserted-by":"publisher","unstructured":"A. Lecube, G. Pach\u00f3n, J. Petriz, C. Hern\u00e1ndez, R. Sim\u00f3, Phagocytic Activity Is Impaired in Type 2 Diabetes Mellitus and Increases after Metabolic Improvement, PLoS One, vol. 6, no. 8, p. e23366, Aug. 2011, https:\/\/doi.org\/10.1371\/journal.pone.0023366","DOI":"10.1371\/journal.pone.0023366"},{"key":"4644_CR30","doi-asserted-by":"publisher","unstructured":"T. Komura, Y. Sakai, M. Honda, T. Takamura, K. Matsushima, S. Kaneko, CD14\u2009+\u2009Monocytes Are Vulnerable and Functionally Impaired Under Endoplasmic Reticulum Stress in Patients With Type 2 Diabetes, Diabetes, vol. 59, no. 3, pp. 634\u2013643, Mar. 2010, https:\/\/doi.org\/10.2337\/db09-0659","DOI":"10.2337\/db09-0659"},{"key":"4644_CR31","doi-asserted-by":"publisher","unstructured":"T.N. Le, J.E. Nestler, J.F. Strauss, E.P. Wickham, Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol. Metabolism. 23(1), 32\u201340 (Jan. 2012). https:\/\/doi.org\/10.1016\/j.tem.2011.09.005","DOI":"10.1016\/j.tem.2011.09.005"},{"key":"4644_CR32","doi-asserted-by":"publisher","unstructured":"E. Giovannucci et al., Diabetes and Cancer. Diabetes Care. 33(7), 1674\u20131685 (Jul. 2010). https:\/\/doi.org\/10.2337\/dc10-0666","DOI":"10.2337\/dc10-0666"},{"key":"4644_CR33","doi-asserted-by":"publisher","unstructured":"E.L. Ding, Y. Song, V.S. Malik, S. Liu, Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes. JAMA 295(11), 1288 (Mar. 2006). https:\/\/doi.org\/10.1001\/jama.295.11.1288","DOI":"10.1001\/jama.295.11.1288"},{"key":"4644_CR34","doi-asserted-by":"publisher","unstructured":"S. Liu, Q. Sun, Sex differences, endogenous sex-hormone hormones, sex\u2010hormone binding globulin, and exogenous disruptors in diabetes and related metabolic outcomes. J. Diabetes. 10(6), 428\u2013441 (Jun. 2018). https:\/\/doi.org\/10.1111\/1753-0407.12517","DOI":"10.1111\/1753-0407.12517"},{"key":"4644_CR35","doi-asserted-by":"publisher","unstructured":"D.P. Turner, Advanced glycation end-products: a biological consequence of lifestyle contributing to cancer disparity. Cancer Res. 75(10), 1925\u20131929 (May 2015). https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0169","DOI":"10.1158\/0008-5472.CAN-15-0169"},{"key":"4644_CR36","doi-asserted-by":"publisher","unstructured":"C. Piperi, C. Adamopoulos, A.G. Papavassiliou, Potential of glycative stress targeting for cancer prevention. Cancer Lett. 390, 153\u2013159 (Apr. 2017). https:\/\/doi.org\/10.1016\/j.canlet.2017.01.020","DOI":"10.1016\/j.canlet.2017.01.020"},{"key":"4644_CR37","doi-asserted-by":"publisher","unstructured":"A.M.Y. Zhang, E.A. Wellberg, J.L. Kopp, J.D. Johnson, Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab. J. 45(3), 285\u2013311 (May 2021). https:\/\/doi.org\/10.4093\/dmj.2020.0250","DOI":"10.4093\/dmj.2020.0250"},{"key":"4644_CR38","doi-asserted-by":"publisher","unstructured":"M. Lee-Rueckert et al., Obesity-induced changes in cancer cells and their microenvironment: Mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism. Semin Cancer Biol. 93, 36\u201351 (Aug. 2023). https:\/\/doi.org\/10.1016\/j.semcancer.2023.05.002","DOI":"10.1016\/j.semcancer.2023.05.002"},{"key":"4644_CR39","doi-asserted-by":"publisher","unstructured":"R.H. Eckel, A. Farooki, R.R. Henry, G.G. Koch, L.A. Leiter, Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice? Clin. Diabetes, vol. 37, no. 4, pp. 316\u2013337, Oct. 2019, https:\/\/doi.org\/10.2337\/cd19-0001","DOI":"10.2337\/cd19-0001"},{"key":"4644_CR40","doi-asserted-by":"publisher","unstructured":"M.N.A. Kamarudin, M.M.R. Sarker, J.-R. Zhou, I. Parhar, Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects., J. Exp. Clin. Cancer Res., vol. 38, no. 1, p. 491, Dec. 2019, https:\/\/doi.org\/10.1186\/s13046-019-1495-2","DOI":"10.1186\/s13046-019-1495-2"},{"key":"4644_CR41","doi-asserted-by":"publisher","unstructured":"M. Zakikhani, R.J.O. Dowling, N. Sonenberg, M.N. Pollak, The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase., Cancer Prev. Res. (Phila)., vol. 1, no. 5, pp. 369\u201375, Oct. 2008, https:\/\/doi.org\/10.1158\/1940-6207.CAPR-08-0081","DOI":"10.1158\/1940-6207.CAPR-08-0081"},{"key":"4644_CR42","doi-asserted-by":"publisher","unstructured":"K. Bhalla et al., Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev. Res. (Phila). 5(4), 544\u2013552 (Apr. 2012). https:\/\/doi.org\/10.1158\/1940-6207.CAPR-11-0228","DOI":"10.1158\/1940-6207.CAPR-11-0228"},{"key":"4644_CR43","doi-asserted-by":"publisher","unstructured":"G. Amable et al., Jul., Metformin inhibits \u03b2-catenin phosphorylation on Ser-552 through an AMPK\/PI3K\/Akt pathway in colorectal cancer cells., Int. J. Biochem. Cell Biol., vol. 112, pp. 88\u201394, 2019, https:\/\/doi.org\/10.1016\/j.biocel.2019.05.004","DOI":"10.1016\/j.biocel.2019.05.004"},{"issue":"1","key":"4644_CR44","doi-asserted-by":"publisher","first-page":"e84369","DOI":"10.1371\/journal.pone.0084369","volume":"9","author":"P Nangia-Makker","year":"2014","unstructured":"P. Nangia-Makker et al., Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One. 9(1), e84369 (2014). https:\/\/doi.org\/10.1371\/journal.pone.0084369","journal-title":"PLoS One"},{"key":"4644_CR45","doi-asserted-by":"publisher","unstructured":"I.N. Alimova et al., Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell. Cycle. 8(6), 909\u2013915 (Mar. 2009). https:\/\/doi.org\/10.4161\/cc.8.6.7933","DOI":"10.4161\/cc.8.6.7933"},{"key":"4644_CR46","doi-asserted-by":"publisher","unstructured":"I. Ben Sahra et al., Mar., Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells., Cancer Res., vol. 70, no. 6, pp. 2465\u201375, 2010, https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2782","DOI":"10.1158\/0008-5472.CAN-09-2782"},{"key":"4644_CR47","doi-asserted-by":"publisher","unstructured":"J.A. Zell et al., Feb., A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index., Cancer Prev. Res. (Phila)., vol. 13, no. 2, pp. 203\u2013212, 2020, https:\/\/doi.org\/10.1158\/1940-6207.CAPR-18-0262","DOI":"10.1158\/1940-6207.CAPR-18-0262"},{"key":"4644_CR48","doi-asserted-by":"publisher","unstructured":"B. Bonanni et al., Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J. Clin. Oncol. 30(21), 2593\u20132600 (Jul. 2012). https:\/\/doi.org\/10.1200\/JCO.2011.39.3769","DOI":"10.1200\/JCO.2011.39.3769"},{"key":"4644_CR49","doi-asserted-by":"publisher","unstructured":"S. Pusceddu et al., Dec., Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study., Cancers (Basel)., vol. 14, no. 1, 2021, https:\/\/doi.org\/10.3390\/cancers14010069","DOI":"10.3390\/cancers14010069"},{"key":"4644_CR50","doi-asserted-by":"publisher","unstructured":"M. Reni et al., (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Clin. Cancer Res. 22(5), 1076\u20131085 (Mar. 2016). https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1722","DOI":"10.1158\/1078-0432.CCR-15-1722"},{"key":"4644_CR51","unstructured":"C. Blanquicett, J. Roman, C.M. Hart, Thiazolidinediones as anti-cancer agents., Cancer Ther., vol. 6, no. A, pp. 25\u201334, 2008"},{"key":"4644_CR52","doi-asserted-by":"publisher","unstructured":"F. Yin et al., Sep., Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators., Biochem. Biophys. Res. Commun., vol. 286, no. 5, pp. 916\u201322, 2001, https:\/\/doi.org\/10.1006\/bbrc.2001.5491","DOI":"10.1006\/bbrc.2001.5491"},{"key":"4644_CR53","doi-asserted-by":"publisher","unstructured":"M. Toyota et al., Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci. 70, 1565\u20131575 (Feb. 2002). https:\/\/doi.org\/10.1016\/s0024-3205(01)01524-7","DOI":"10.1016\/s0024-3205(01)01524-7"},{"key":"4644_CR54","doi-asserted-by":"publisher","unstructured":"H. Sato et al., Nov., Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists., Br. J. Cancer, vol. 83, no. 10, pp. 1394\u2013400, 2000, https:\/\/doi.org\/10.1054\/bjoc.2000.1457","DOI":"10.1054\/bjoc.2000.1457"},{"key":"4644_CR55","doi-asserted-by":"publisher","unstructured":"V.G. Keshamouni et al., Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene. 23(1), 100\u2013108 (Jan. 2004). https:\/\/doi.org\/10.1038\/sj.onc.1206885","DOI":"10.1038\/sj.onc.1206885"},{"key":"4644_CR56","doi-asserted-by":"publisher","unstructured":"W. Motomura et al., Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int. J. Cancer. 108(1), 41\u201346 (Jan. 2004). https:\/\/doi.org\/10.1002\/ijc.11561","DOI":"10.1002\/ijc.11561"},{"key":"4644_CR57","doi-asserted-by":"publisher","unstructured":"M. Toyoda et al., A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut. 50(4), 563\u2013567 (Apr. 2002). https:\/\/doi.org\/10.1136\/gut.50.4.563","DOI":"10.1136\/gut.50.4.563"},{"key":"4644_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fendo.2017.00031","volume":"8","author":"V Vella","year":"2017","unstructured":"V. Vella, M.L. Nicolosi, S. Giuliano, M. Bellomo, A. Belfiore, R. Malaguarnera, PPAR-\u03b3 Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. Front. Endocrinol. (Lausanne). 8, 31 (2017). https:\/\/doi.org\/10.3389\/fendo.2017.00031","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4644_CR59","doi-asserted-by":"publisher","unstructured":"P. Sarraf et al., Sep., Differentiation and reversal of malignant changes in colon cancer through PPARgamma., Nat. Med., vol. 4, no. 9, pp. 1046\u201352, 1998, https:\/\/doi.org\/10.1038\/2030","DOI":"10.1038\/2030"},{"key":"4644_CR60","doi-asserted-by":"publisher","unstructured":"B. Shen et al., PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br. J. Cancer. 106(9), 1486\u20131494 (Apr. 2012). https:\/\/doi.org\/10.1038\/bjc.2012.130","DOI":"10.1038\/bjc.2012.130"},{"key":"4644_CR61","doi-asserted-by":"publisher","unstructured":"B. Walter et al., Pioglitazone, etoricoxib, interferon-\u03b1, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. Med. Oncol. 29(2), 799\u2013805 (Jun. 2012). https:\/\/doi.org\/10.1007\/s12032-011-9982-0","DOI":"10.1007\/s12032-011-9982-0"},{"key":"4644_CR62","doi-asserted-by":"publisher","unstructured":"M.H. Kulke, E.K. Bergsland, J.C. Yao, Glycemic control in patients with insulinoma treated with everolimus. N Engl. J. Med. 360(2), 195\u2013197 (Jan. 2009). https:\/\/doi.org\/10.1056\/NEJMc0806740","DOI":"10.1056\/NEJMc0806740"},{"key":"4644_CR63","doi-asserted-by":"publisher","unstructured":"H.J. Burstein, G.D. Demetri, E. Mueller, P. Sarraf, B.M. Spiegelman, E.P. Winer, Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study., Breast Cancer Res. Treat., vol. 79, no. 3, pp. 391\u20137, Jun. 2003, https:\/\/doi.org\/10.1023\/a:1024038127156","DOI":"10.1023\/a:1024038127156"},{"key":"4644_CR64","doi-asserted-by":"publisher","unstructured":"R.L. Keith et al., Oct., A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers., Cancer Prev. Res. (Phila)., vol. 12, no. 10, pp. 721\u2013730, 2019, https:\/\/doi.org\/10.1158\/1940-6207.CAPR-19-0006","DOI":"10.1158\/1940-6207.CAPR-19-0006"},{"key":"4644_CR65","doi-asserted-by":"publisher","unstructured":"L. Wang, R. Xu, D.C. Kaelber, N.A. Berger, Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw. Open. 7(7), e2421305 (Jul. 2024). https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21305","DOI":"10.1001\/jamanetworkopen.2024.21305"},{"key":"4644_CR66","doi-asserted-by":"publisher","unstructured":"H. Ligumsky et al., Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells. Med. Oncol. 41(6), 138 (May 2024). https:\/\/doi.org\/10.1007\/s12032-024-02390-w","DOI":"10.1007\/s12032-024-02390-w"},{"key":"4644_CR67","doi-asserted-by":"publisher","unstructured":"S. Kim et al., FAM3C in Cancer-Associated Adipocytes Promotes Breast Cancer Cell Survival and Metastasis. Cancer Res. 84(4), 545\u2013559 (Feb. 2024). https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1641","DOI":"10.1158\/0008-5472.CAN-23-1641"},{"key":"4644_CR68","doi-asserted-by":"publisher","unstructured":"H. Zhao, X. Jiang, L. Duan, L. Yang, W. Wang, Z. Ren, Liraglutide suppresses the metastasis of PANC-1 co-cultured with pancreatic stellate cells through modulating intracellular calcium content., Endocr. J., vol. 66, no. 12, pp. 1053\u20131062, Dec. 2019, https:\/\/doi.org\/10.1507\/endocrj.EJ19-0215","DOI":"10.1507\/endocrj.EJ19-0215"},{"key":"4644_CR69","doi-asserted-by":"publisher","unstructured":"A. Kosowska et al., Nov., Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells., Endocr. Connect., vol. 6, no. 8, pp. 856\u2013865, 2017, https:\/\/doi.org\/10.1530\/EC-17-0294","DOI":"10.1530\/EC-17-0294"},{"key":"4644_CR70","doi-asserted-by":"publisher","unstructured":"X. Lu et al., Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6\/STAT3 signaling in hepatocellular carcinoma. Transl Oncol. 14(1), 100872 (Jan. 2021). https:\/\/doi.org\/10.1016\/j.tranon.2020.100872","DOI":"10.1016\/j.tranon.2020.100872"},{"key":"4644_CR71","doi-asserted-by":"publisher","unstructured":"I. Reppo, M. Jakobson, V. Volke, Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes., Int. J. Mol. Sci., vol. 24, no. 6, Mar. 2023, https:\/\/doi.org\/10.3390\/ijms24065714","DOI":"10.3390\/ijms24065714"},{"key":"4644_CR72","doi-asserted-by":"publisher","unstructured":"C. De Barra et al., Jul., Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function., Obesity (Silver Spring)., vol. 31, no. 7, pp. 1787\u20131797, 2023, https:\/\/doi.org\/10.1002\/oby.23772","DOI":"10.1002\/oby.23772"},{"key":"4644_CR73","doi-asserted-by":"publisher","unstructured":"J.M. Tatsch et al., Dec., Dulaglutide as a demethylating agent to improve the outcome of breast cancer., Epigenomics, vol. 15, no. 24, pp. 1309\u20131322, 2023, https:\/\/doi.org\/10.2217\/epi-2023-0332","DOI":"10.2217\/epi-2023-0332"},{"key":"4644_CR74","doi-asserted-by":"publisher","unstructured":"X.-X. Zhu, Z.-H. Feng, L.-Z. Liu, Y. Zhang, Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5\u2019-monophosphate (AMP)-activated protein kinase signaling pathway. Chin. Med. J. (Engl). 134(5), 576\u2013578 (Jan. 2021). https:\/\/doi.org\/10.1097\/CM9.0000000000001363","DOI":"10.1097\/CM9.0000000000001363"},{"key":"4644_CR75","doi-asserted-by":"publisher","first-page":"901559","DOI":"10.3389\/fphar.2022.901559","volume":"13","author":"G Tong","year":"2022","unstructured":"G. Tong et al., Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K\/AKT\/mTOR Signaling Pathway. Front. Pharmacol. 13, 901559 (2022). https:\/\/doi.org\/10.3389\/fphar.2022.901559","journal-title":"Front. Pharmacol."},{"key":"4644_CR76","doi-asserted-by":"publisher","unstructured":"X. Zhang et al., Dec., GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells., Cell. Mol. Biol. (Noisy-le-grand)., vol. 69, no. 14, pp. 221\u2013225, 2023, https:\/\/doi.org\/10.14715\/cmb\/2023.69.14.37","DOI":"10.14715\/cmb\/2023.69.14.37"},{"key":"4644_CR77","doi-asserted-by":"publisher","unstructured":"W. van den Brink, A. Emerenciana, F. Bellanti, O. Della Pasqua, J.W. van der Laan, Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents. Toxicol. Appl. Pharmacol. 320, 51\u201359 (Apr. 2017). https:\/\/doi.org\/10.1016\/j.taap.2017.02.010","DOI":"10.1016\/j.taap.2017.02.010"},{"key":"4644_CR78","doi-asserted-by":"publisher","unstructured":"D.S. Popovic, D. Patoulias, L.S. Popovic, P. Karakasis, N. Papanas, C.S. Mantzoros, Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Diabetes Res. Clin. Pract. 213, 111758 (Jul. 2024). https:\/\/doi.org\/10.1016\/j.diabres.2024.111758","DOI":"10.1016\/j.diabres.2024.111758"},{"key":"4644_CR79","doi-asserted-by":"publisher","unstructured":"P. Busek, J.S. Duke-Cohan, A. Sedo, Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease? Cancers (Basel)., vol. 14, no. 9, Apr. 2022, https:\/\/doi.org\/10.3390\/cancers14092072","DOI":"10.3390\/cancers14092072"},{"key":"4644_CR80","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3389\/fonc.2020.00405","volume":"10","author":"C Shah","year":"2020","unstructured":"C. Shah et al., Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer. Front. Oncol. 10, 405 (2020). https:\/\/doi.org\/10.3389\/fonc.2020.00405","journal-title":"Front. Oncol."},{"key":"4644_CR81","doi-asserted-by":"publisher","unstructured":"R. Pradhan, O.H.Y. Yu, R.W. Platt, L. Azoulay, Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study. BMJ Open. Diabetes Res. Care. 11(6) (Nov. 2023). https:\/\/doi.org\/10.1136\/bmjdrc-2023-003550","DOI":"10.1136\/bmjdrc-2023-003550"},{"key":"4644_CR82","doi-asserted-by":"publisher","unstructured":"C. Hollande et al., Mar., Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth., Nat. Immunol., vol. 20, no. 3, pp. 257\u2013264, 2019, https:\/\/doi.org\/10.1038\/s41590-019-0321-5","DOI":"10.1038\/s41590-019-0321-5"},{"key":"4644_CR83","doi-asserted-by":"publisher","unstructured":"C.-J. Qin et al., Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2. Cancer Lett. 420, 26\u201337 (Apr. 2018). https:\/\/doi.org\/10.1016\/j.canlet.2018.01.064","DOI":"10.1016\/j.canlet.2018.01.064"},{"key":"4644_CR84","doi-asserted-by":"publisher","unstructured":"J. Wang, C.H. Kim, Malignancies associated with DPP4 inhibitors and GLP1 receptor agonists: Data from a large real-world database., Journal of Clinical Oncology, vol. 38, no. 15_suppl, pp. 1567\u20131567, May 2020, https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.1567","DOI":"10.1200\/JCO.2020.38.15_suppl.1567"},{"key":"4644_CR85","doi-asserted-by":"publisher","unstructured":"I.-I. Ng et al., Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells. J. Immunother Cancer. 12(3) (Mar. 2024). https:\/\/doi.org\/10.1136\/jitc-2023-008254","DOI":"10.1136\/jitc-2023-008254"},{"key":"4644_CR86","doi-asserted-by":"publisher","unstructured":"H. Kuang, L. Liao, H. Chen, Q. Kang, X. Shu, Y. Wang, Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma., Med. Sci. Monit., vol. 23, pp. 3737\u20133745, Aug. 2017, https:\/\/doi.org\/10.12659\/msm.902530","DOI":"10.12659\/msm.902530"},{"key":"4644_CR87","doi-asserted-by":"publisher","unstructured":"T. Jojima et al., The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Int. J. Mol. Sci. 20(20) (Oct. 2019). https:\/\/doi.org\/10.3390\/ijms20205237","DOI":"10.3390\/ijms20205237"},{"key":"4644_CR88","doi-asserted-by":"publisher","first-page":"728047","DOI":"10.3389\/fonc.2021.728047","volume":"11","author":"R Li","year":"2021","unstructured":"R. Li et al., Antidiabetic DPP-4 Inhibitors Reprogram Tumor Microenvironment That Facilitates Murine Breast Cancer Metastasis Through Interaction With Cancer Cells via a ROS-NF-\u043aB-NLRP3 Axis. Front. Oncol. 11, 728047 (2021). https:\/\/doi.org\/10.3389\/fonc.2021.728047","journal-title":"Front. Oncol."},{"key":"4644_CR89","doi-asserted-by":"publisher","unstructured":"A. Pandey et al., Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities. Cancers (Basel). 17(3) (Jan. 2025). https:\/\/doi.org\/10.3390\/cancers17030466","DOI":"10.3390\/cancers17030466"},{"key":"4644_CR90","doi-asserted-by":"publisher","unstructured":"A.R. Nasiri, M.R. Rodrigues, Z. Li, B.P. Leitner, R.J. Perry, SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer Metab. 7(10) (2019). https:\/\/doi.org\/10.1186\/s40170-019-0203-1","DOI":"10.1186\/s40170-019-0203-1"},{"key":"4644_CR91","doi-asserted-by":"publisher","unstructured":"J. Zhou et al., Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed. Pharmacother. 132, 110821 (Dec. 2020). https:\/\/doi.org\/10.1016\/j.biopha.2020.110821","DOI":"10.1016\/j.biopha.2020.110821"},{"key":"4644_CR92","doi-asserted-by":"publisher","first-page":"1114582","DOI":"10.3389\/fimmu.2023.1114582","volume":"14","author":"CK Keerthana","year":"2023","unstructured":"C.K. Keerthana et al., The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment. Front. Immunol. 14, 1114582 (2023). https:\/\/doi.org\/10.3389\/fimmu.2023.1114582","journal-title":"Front. Immunol."},{"key":"4644_CR93","doi-asserted-by":"publisher","unstructured":"L.A. Villani et al., The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol. Metab. 5(10), 1048\u20131056 (Oct. 2016). https:\/\/doi.org\/10.1016\/j.molmet.2016.08.014","DOI":"10.1016\/j.molmet.2016.08.014"},{"key":"4644_CR94","doi-asserted-by":"publisher","unstructured":"Y. Wang et al., SGLT2 inhibition restrains thyroid cancer growth via G1\/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways. Cancer Cell. Int. 22(1), 74 (Feb. 2022). https:\/\/doi.org\/10.1186\/s12935-022-02496-z","DOI":"10.1186\/s12935-022-02496-z"},{"key":"4644_CR95","doi-asserted-by":"publisher","unstructured":"J. Luo et al., Dec., Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1\u03b1 Protein Synthesis via AKT\/mTOR Pathway., Int. J. Mol. Sci., vol. 22, no. 24, 2021, https:\/\/doi.org\/10.3390\/ijms222413336","DOI":"10.3390\/ijms222413336"},{"key":"4644_CR96","doi-asserted-by":"publisher","unstructured":"S. Copur, A.B. Yildiz, A. Covic, M. Kanbay, Is there any robust evidence showing that <\u2009scp>SGLT2 inhibitor predisposes to cancer? Eur. J. Clin. Invest. 54(2) (Feb. 2024). https:\/\/doi.org\/10.1111\/eci.14131","DOI":"10.1111\/eci.14131"},{"key":"4644_CR97","doi-asserted-by":"publisher","unstructured":"R.J. Perry, G.I. Shulman, Mechanistic Links between Obesity, Insulin, and Cancer. Trends Cancer. 6(2), 75\u201378 (Feb. 2020). https:\/\/doi.org\/10.1016\/j.trecan.2019.12.003","DOI":"10.1016\/j.trecan.2019.12.003"},{"key":"4644_CR98","doi-asserted-by":"publisher","unstructured":"Z. Wang et al., 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer. Cancer Res. 79(7), 1438\u20131450 (Apr. 2019). https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1220","DOI":"10.1158\/0008-5472.CAN-18-1220"},{"key":"4644_CR99","doi-asserted-by":"publisher","unstructured":"I. Nemazanyy, C. Espeillac, M. Pende, G. Panasyuk, Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression., Biochem. Soc. Trans., vol. 41, no. 4, pp. 917\u201322, Aug. 2013, https:\/\/doi.org\/10.1042\/BST20130034","DOI":"10.1042\/BST20130034"},{"key":"4644_CR100","doi-asserted-by":"publisher","unstructured":"Y. Gong et al., Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation. Neuro Oncol. 18(1), 48\u201357 (Jan. 2016). https:\/\/doi.org\/10.1093\/neuonc\/nov096","DOI":"10.1093\/neuonc\/nov096"},{"key":"4644_CR101","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fendo.2019.00594","volume":"10","author":"X Sheng","year":"2019","unstructured":"X. Sheng et al., The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling. Front. Endocrinol. (Lausanne). 10, 594 (2019). https:\/\/doi.org\/10.3389\/fendo.2019.00594","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4644_CR102","doi-asserted-by":"publisher","unstructured":"J. Jiang et al., Oncogenic activity of insulin in the development of non-small cell lung carcinoma. Oncol. Lett. 15(1), 447\u2013452 (Jan. 2018). https:\/\/doi.org\/10.3892\/ol.2017.7347","DOI":"10.3892\/ol.2017.7347"},{"key":"4644_CR103","unstructured":"J. Kurniawan, M. Teressa, Insulin Use and The Risk of Hepatocellular Carcinoma: Insights and Implications., Acta Med. Indones., vol. 56, no. 1, pp. 107\u2013113, Jan. 2024"},{"key":"4644_CR104","doi-asserted-by":"publisher","unstructured":"X. Chen, H. Liang, Q. Song, X. Xu, D. Cao, Insulin promotes progression of colon cancer by upregulation of ACAT1. Lipids Health Dis. 17(1), 122 (May 2018). https:\/\/doi.org\/10.1186\/s12944-018-0773-x","DOI":"10.1186\/s12944-018-0773-x"},{"key":"4644_CR105","doi-asserted-by":"publisher","unstructured":"M. Shimobayashi et al., Apr., Insulin resistance causes inflammation in adipose tissue., J. Clin. Invest., vol. 128, no. 4, pp. 1538\u20131550, 2018, https:\/\/doi.org\/10.1172\/JCI96139","DOI":"10.1172\/JCI96139"},{"key":"4644_CR106","doi-asserted-by":"publisher","unstructured":"R. Krogh-Madsen, P. Plomgaard, P. Keller, C. Keller, B.K. Pedersen, Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue. Am. J. Physiol. Endocrinol. Metab. 286(2), E234\u2013E238 (Feb. 2004). https:\/\/doi.org\/10.1152\/ajpendo.00274.2003","DOI":"10.1152\/ajpendo.00274.2003"},{"key":"4644_CR107","doi-asserted-by":"publisher","unstructured":"V.P. Brahmkhatri, C. Prasanna, H.S. Atreya, Insulin-like growth factor system in cancer: novel targeted therapies., Biomed Res. Int., vol. 2015, p. 538019, 2015. https:\/\/doi.org\/10.1155\/2015\/538019","DOI":"10.1155\/2015\/538019"},{"issue":"1","key":"4644_CR108","doi-asserted-by":"publisher","first-page":"e84532","DOI":"10.1371\/journal.pone.0084532","volume":"9","author":"H-S Kang","year":"2014","unstructured":"H.-S. Kang et al., Association of polymorphisms and haplotypes in the insulin-like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women. PLoS One. 9(1), e84532 (2014). https:\/\/doi.org\/10.1371\/journal.pone.0084532","journal-title":"PLoS One"},{"key":"4644_CR109","doi-asserted-by":"publisher","unstructured":"X. Dong, M. Javle, K.R. Hess, R. Shroff, J.L. Abbruzzese, D. Li, Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer., Gastroenterology, vol. 139, no. 2, pp. 464\u201373, 473.e1\u20133, Aug. 2010, https:\/\/doi.org\/10.1053\/j.gastro.2010.04.042","DOI":"10.1053\/j.gastro.2010.04.042"},{"key":"4644_CR110","doi-asserted-by":"publisher","first-page":"874344","DOI":"10.3389\/fendo.2022.874344","volume":"13","author":"H Zhao","year":"2022","unstructured":"H. Zhao et al., Sulfonylurea and Cancer Risk Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. Front. Endocrinol. (Lausanne). 13, 874344 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.874344","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4644_CR111","doi-asserted-by":"publisher","unstructured":"M. Rezazadeh et al., Effect of diabetes mellitus type 2 and sulfonylurea on colorectal cancer development: a case-control study. BMC Gastroenterol. 24(1), 382 (Oct. 2024). https:\/\/doi.org\/10.1186\/s12876-024-03477-4","DOI":"10.1186\/s12876-024-03477-4"},{"key":"4644_CR112","doi-asserted-by":"publisher","unstructured":"M. N\u00fa\u00f1ez et al., Glibenclamide inhibits cell growth by inducing G0\/G1 arrest in the human breast cancer cell line MDA-MB-231. BMC Pharmacol. Toxicol. 14(6) (Jan. 2013). https:\/\/doi.org\/10.1186\/2050-6511-14-6","DOI":"10.1186\/2050-6511-14-6"},{"key":"4644_CR113","doi-asserted-by":"publisher","unstructured":"H. Chen et al., Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression. Cancer Lett. 536, 215611 (Jun. 2022). https:\/\/doi.org\/10.1016\/j.canlet.2022.215611","DOI":"10.1016\/j.canlet.2022.215611"},{"key":"4644_CR114","doi-asserted-by":"publisher","unstructured":"F.B. Nunes et al., Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol. Res. 49(5), 449\u2013453 (May 2004). https:\/\/doi.org\/10.1016\/j.phrs.2003.10.015","DOI":"10.1016\/j.phrs.2003.10.015"},{"issue":"9","key":"4644_CR115","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.2174\/1871520621666210910085733","volume":"22","author":"G Mao","year":"2022","unstructured":"G. Mao et al., Glipizide Combined with ANP Suppresses Breast Cancer Growth and Metastasis by Inhibiting Angiogenesis through VEGF\/VEGFR2 Signaling. Anticancer Agents Med. Chem. 22(9), 1735\u20131741 (2022). https:\/\/doi.org\/10.2174\/1871520621666210910085733","journal-title":"Anticancer Agents Med. Chem."},{"key":"4644_CR116","doi-asserted-by":"crossref","unstructured":"Effect of, intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group., Lancet, vol. 352, no. 9131, pp. 854\u201365, Sep. 1998","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"4644_CR117","doi-asserted-by":"publisher","unstructured":"R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A.W. Neil, 10-year follow-up of intensive glucose control in type 2 diabetes., N. Engl. J. Med., vol. 359, no. 15, pp. 1577\u201389, Oct. 2008, https:\/\/doi.org\/10.1056\/NEJMoa0806470","DOI":"10.1056\/NEJMoa0806470"},{"key":"4644_CR118","doi-asserted-by":"publisher","unstructured":"W.C. Knowler et al., Feb., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin., N. Engl. J. Med., vol. 346, no. 6, pp. 393\u2013403, 2002, https:\/\/doi.org\/10.1056\/NEJMoa012512","DOI":"10.1056\/NEJMoa012512"},{"key":"4644_CR119","doi-asserted-by":"publisher","unstructured":"A. Kooy et al., Mar., Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus., Arch. Intern. Med., vol. 169, no. 6, pp. 616\u201325, 2009, https:\/\/doi.org\/10.1001\/archinternmed.2009.20","DOI":"10.1001\/archinternmed.2009.20"},{"key":"4644_CR120","doi-asserted-by":"publisher","unstructured":"S. Gillessen et al., Aug., Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol., Lancet Oncol., vol. 26, no. 8, pp. 1018\u20131030, 2025, https:\/\/doi.org\/10.1016\/S1470-2045(25)00231-1","DOI":"10.1016\/S1470-2045(25)00231-1"},{"key":"4644_CR121","doi-asserted-by":"publisher","unstructured":"R. Shi et al., Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy. JAMA Oncol. (Jan. 2026). https:\/\/doi.org\/10.1001\/jamaoncol.2025.5869","DOI":"10.1001\/jamaoncol.2025.5869"},{"key":"4644_CR122","doi-asserted-by":"publisher","unstructured":"J.A. Dormandy et al., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 366(9493), 1279\u20131289 (Oct. 2005). https:\/\/doi.org\/10.1016\/S0140-6736(05)67528-9","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"4644_CR123","doi-asserted-by":"publisher","unstructured":"DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators et al. et al., Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial., Lancet, vol. 368, no. 9541, pp. 1096\u2013105, Sep. 2006, https:\/\/doi.org\/10.1016\/S0140-6736(06)69420-8","DOI":"10.1016\/S0140-6736(06)69420-8"},{"key":"4644_CR124","doi-asserted-by":"publisher","unstructured":"S.E. Kahn et al., Dec., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy., N. Engl. J. Med., vol. 355, no. 23, pp. 2427\u201343, 2006, https:\/\/doi.org\/10.1056\/NEJMoa066224","DOI":"10.1056\/NEJMoa066224"},{"key":"4644_CR125","doi-asserted-by":"publisher","unstructured":"P.D. Home et al., Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 373, 2125\u20132135 (Jun. 2009). https:\/\/doi.org\/10.1016\/S0140-6736(09)60953-3","DOI":"10.1016\/S0140-6736(09)60953-3"},{"key":"4644_CR126","doi-asserted-by":"publisher","unstructured":"P.D. Home et al., Sep., Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials., Diabetologia, vol. 53, no. 9, pp. 1838\u201345, 2010, https:\/\/doi.org\/10.1007\/s00125-010-1804-y","DOI":"10.1007\/s00125-010-1804-y"},{"key":"4644_CR127","doi-asserted-by":"publisher","unstructured":"S.P. Marso et al., Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl. J. Med. 375(4), 311\u2013322 (Jul. 2016). https:\/\/doi.org\/10.1056\/NEJMoa1603827","DOI":"10.1056\/NEJMoa1603827"},{"key":"4644_CR128","doi-asserted-by":"publisher","first-page":"645566","DOI":"10.3389\/fendo.2021.645566","volume":"12","author":"MA Nauck","year":"2021","unstructured":"M.A. Nauck, D.R. Quast, Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Front. Endocrinol. (Lausanne). 12, 645566 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.645566","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4644_CR129","doi-asserted-by":"publisher","unstructured":"M. Husain et al., Aug., Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes., N. Engl. J. Med., vol. 381, no. 9, pp. 841\u2013851, 2019, https:\/\/doi.org\/10.1056\/NEJMoa1901118","DOI":"10.1056\/NEJMoa1901118"},{"key":"4644_CR130","doi-asserted-by":"publisher","unstructured":"R.R. Holman et al., Sep., Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes., N. Engl. J. Med., vol. 377, no. 13, pp. 1228\u20131239, 2017, https:\/\/doi.org\/10.1056\/NEJMoa1612917","DOI":"10.1056\/NEJMoa1612917"},{"key":"4644_CR131","doi-asserted-by":"publisher","unstructured":"H.C. Gerstein et al., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 394(10193), 121\u2013130 (Jul. 2019). https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"4644_CR132","doi-asserted-by":"publisher","unstructured":"A.B.M. Kamrul-Hasan, M.S. Alam, D. Dutta, T. Sasikanth, F.T.Z. Aalpona, L. Nagendra, Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis., Endocrinol. Metab. (Seoul)., vol. 40, no. 1, pp. 112\u2013124, Feb. 2025, https:\/\/doi.org\/10.3803\/EnM.2024.2164","DOI":"10.3803\/EnM.2024.2164"},{"key":"4644_CR133","doi-asserted-by":"publisher","unstructured":"L.A. Leiter et al., Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Diabetes Obes. Metab. 18(2), 186\u2013190 (Feb. 2016). https:\/\/doi.org\/10.1111\/dom.12582","DOI":"10.1111\/dom.12582"},{"key":"4644_CR134","doi-asserted-by":"publisher","unstructured":"J.B. Buse et al., Pancreatic Safety of Sitagliptin in the TECOS Study. Diabetes Care. 40(2), 164\u2013170 (Feb. 2017). https:\/\/doi.org\/10.2337\/dc15-2780","DOI":"10.2337\/dc15-2780"},{"key":"4644_CR135","doi-asserted-by":"publisher","unstructured":"J. Rosenstock et al., Jan., Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial., JAMA, vol. 321, no. 1, pp. 69\u201379, 2019, https:\/\/doi.org\/10.1001\/jama.2018.18269","DOI":"10.1001\/jama.2018.18269"},{"key":"4644_CR136","doi-asserted-by":"publisher","unstructured":"B. Zinman et al., Nov., Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, New England Journal of Medicine, vol. 373, no. 22, pp. 2117\u20132128, 2015, https:\/\/doi.org\/10.1056\/NEJMoa1504720","DOI":"10.1056\/NEJMoa1504720"},{"key":"4644_CR137","doi-asserted-by":"publisher","unstructured":"B. Neal et al., Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N. Engl. J. Med. 377(7), 644\u2013657 (Aug. 2017). https:\/\/doi.org\/10.1056\/NEJMoa1611925","DOI":"10.1056\/NEJMoa1611925"},{"key":"4644_CR138","doi-asserted-by":"publisher","unstructured":"S.D. Wiviott et al., Jan., Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol. 380, no. 4, pp. 347\u2013357, 2019, https:\/\/doi.org\/10.1056\/NEJMoa1812389","DOI":"10.1056\/NEJMoa1812389"},{"key":"4644_CR139","doi-asserted-by":"publisher","unstructured":"C.P. Cannon et al., Oct., Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes, New England Journal of Medicine, vol. 383, no. 15, pp. 1425\u20131435, 2020, https:\/\/doi.org\/10.1056\/NEJMoa2004967","DOI":"10.1056\/NEJMoa2004967"},{"key":"4644_CR140","doi-asserted-by":"publisher","unstructured":"H. Tang, Q. Dai, W. Shi, S. Zhai, Y. Song, J. Han, SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials., Diabetologia, vol. 60, no. 10, pp. 1862\u20131872, Oct. 2017, https:\/\/doi.org\/10.1007\/s00125-017-4370-8","DOI":"10.1007\/s00125-017-4370-8"},{"key":"4644_CR141","doi-asserted-by":"publisher","unstructured":"I. Dicembrini, B. Nreu, E. Mannucci, M. Monami, Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials., Diabetes Obes. Metab., vol. 21, no. 8, pp. 1871\u20131877, Aug. 2019, https:\/\/doi.org\/10.1111\/dom.13745","DOI":"10.1111\/dom.13745"},{"key":"4644_CR142","doi-asserted-by":"publisher","first-page":"668368","DOI":"10.3389\/fpubh.2021.668368","volume":"9","author":"N Shi","year":"2021","unstructured":"N. Shi et al., SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Front. Public. Health. 9, 668368 (2021). https:\/\/doi.org\/10.3389\/fpubh.2021.668368","journal-title":"Front. Public. Health"},{"key":"4644_CR143","doi-asserted-by":"publisher","unstructured":"Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia,, N. Engl. J. Med. 367(4), 319\u2013328 (Jul. 2012). https:\/\/doi.org\/10.1056\/NEJMoa1203858","DOI":"10.1056\/NEJMoa1203858"},{"key":"4644_CR144","doi-asserted-by":"publisher","unstructured":"R.R. Holman, H. Sourij, R.M. Califf, Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 383(9933), 2008\u20132017 (Jun. 2014). https:\/\/doi.org\/10.1016\/S0140-6736(14)60794-7","DOI":"10.1016\/S0140-6736(14)60794-7"},{"key":"4644_CR145","doi-asserted-by":"publisher","unstructured":"S.P. Marso et al., Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. Am. Heart J. 179, 175\u2013183 (Sep. 2016). https:\/\/doi.org\/10.1016\/j.ahj.2016.06.004","DOI":"10.1016\/j.ahj.2016.06.004"},{"key":"4644_CR146","doi-asserted-by":"publisher","unstructured":"L.G. Hemkens et al., Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 52(9), 1732\u20131744 (Sep. 2009). https:\/\/doi.org\/10.1007\/s00125-009-1418-4","DOI":"10.1007\/s00125-009-1418-4"},{"key":"4644_CR147","doi-asserted-by":"publisher","unstructured":"J.M. Jonasson, R. Ljung, M. Talb\u00e4ck, B. Haglund, S. Gudbj\u00f6rnsd\u00f2ttir, G. Steineck, Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden., Diabetologia, vol. 52, no. 9, pp. 1745\u201354, Sep. 2009, https:\/\/doi.org\/10.1007\/s00125-009-1444-2","DOI":"10.1007\/s00125-009-1444-2"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04644-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04644-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04644-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:59:31Z","timestamp":1781650771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04644-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":147,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4644"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04644-1","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"176"}}